Nuclera Nucleics Stock
Enzymatic DNA synthesis
Sign up today and learn more about Nuclera Nucleics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nuclera Nucleics Stock
Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.
Funding History
| March 2014 | $500K |
|---|---|
| April 2014 | $100K |
| June 2014 | $25K |
| April 2015 | $203K |
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
